Furthermore, using a comparative analysis of RNA-seq and scRNA-seq from prostate cancers, we identified overexpression of VIM, AHNAK2, ANXA1, ANXA2, CD109, CD44, CD59, GPRC5A, HAS, S100A6, TGFBR2 in both cohorts. This evidence concerns the gene ANXA2 and prostate carcinoma.